CN113663083A - 一种漆黄素磷脂复合物和减肥药物/保健食品及其应用 - Google Patents
一种漆黄素磷脂复合物和减肥药物/保健食品及其应用 Download PDFInfo
- Publication number
- CN113663083A CN113663083A CN202110935836.0A CN202110935836A CN113663083A CN 113663083 A CN113663083 A CN 113663083A CN 202110935836 A CN202110935836 A CN 202110935836A CN 113663083 A CN113663083 A CN 113663083A
- Authority
- CN
- China
- Prior art keywords
- fisetin
- weight
- extract
- phospholipid
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XHEFDIBZLJXQHF-UHFFFAOYSA-N Fisetin Natural products C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 title claims abstract description 242
- 235000011990 fisetin Nutrition 0.000 title claims abstract description 139
- -1 Fisetin phospholipid Chemical class 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 235000013402 health food Nutrition 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 22
- 239000002159 nanocrystal Substances 0.000 claims abstract description 17
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 9
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 9
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 9
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 9
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 8
- 206010067125 Liver injury Diseases 0.000 claims abstract description 7
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims description 36
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 235000010388 propyl gallate Nutrition 0.000 claims description 8
- 239000000473 propyl gallate Substances 0.000 claims description 8
- 229940075579 propyl gallate Drugs 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 4
- 229920001531 copovidone Polymers 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- 230000037213 diet Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 244000241838 Lycium barbarum Species 0.000 claims description 2
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 2
- 235000006533 astragalus Nutrition 0.000 claims description 2
- 229940047169 astragalus root extract Drugs 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 241001598107 Imperata Species 0.000 claims 2
- 241000045403 Astragalus propinquus Species 0.000 claims 1
- 244000201986 Cassia tora Species 0.000 claims 1
- 235000014552 Cassia tora Nutrition 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 235000013305 food Nutrition 0.000 abstract description 13
- 240000007171 Imperata cylindrica Species 0.000 abstract description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract description 7
- 235000019206 astragalus extract Nutrition 0.000 abstract description 6
- 230000006609 metabolic stress Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 235000009200 high fat diet Nutrition 0.000 description 15
- 238000013238 high-fat diet model Methods 0.000 description 13
- 238000013218 HFD mouse model Methods 0.000 description 11
- 102000016267 Leptin Human genes 0.000 description 11
- 108010092277 Leptin Proteins 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 229940039781 leptin Drugs 0.000 description 11
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 239000001116 FEMA 4028 Substances 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 229960004853 betadex Drugs 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 229960001701 chloroform Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000003637 steroidlike Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 description 3
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000013224 high-fat diet-induced obese mouse Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 239000006070 nanosuspension Substances 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 241001505404 Deinagkistrodon acutus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001183 FEMA 4495 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000212941 Glehnia Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- CWBZAESOUBENAP-QVNVHUMTSA-N Naringin dihydrochalcone Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C(O)C(C(=O)CCC=3C=CC(O)=CC=3)=C(O)C=2)O[C@H](CO)[C@@H](O)[C@@H]1O CWBZAESOUBENAP-QVNVHUMTSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 241000786103 Steatomys pratensis Species 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003353 bioavailability assay Methods 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 150000002203 fisetin Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于中药制剂/保健食品领域,具体涉及一种漆黄素磷脂复合物和减肥药物/保健食品及其应用。该发明将漆黄素和磷脂溶于有机溶剂中进行反应制备得漆黄素磷脂复合物,按照重量百分计,将漆黄素和/或漆黄素磷脂复合物和/或漆黄素纳米结晶和/或漆黄素环糊精复合物为10‑50%、枸杞提取物10‑50%、决明子提取物10‑50%、白茅根提取物10‑50%、黄芪提取物10‑50%制备得减肥药物/保健食品。本发明提供的漆黄素磷脂复合物及减肥药物/保健食品将漆黄素的水溶性提高了10倍,生物利用度提高了230%,而且具有良好的减重效果,且减重的同时还能够减轻代谢应激引起的肝损伤,安全性高。
Description
技术领域
本发明属于中药制剂/保健食品领域,具体涉及一种漆黄素磷脂复合物和减肥药物/保健食品及其应用。
背景技术
目前公认有效果的减肥药有左旋肉碱、西布曲明、奥利司他等。左旋肉碱能加强脂肪代谢,减少糖原的消耗,促进脂肪、脂肪酸进入,提高脂肪的氧化速率。西布曲明是非苯丙胺类食欲抑制剂,在体内产生代谢产物,可抑制去甲肾上腺素、5-羟色胺和多巴胺的再摄取,加速能量消耗,增加饱食感。奥司利他作用于胃肠道,通过抑制胃肠道的脂肪酶,阻止三酰甘油水解为游离脂肪酸和单酰基甘油酯,减少肠腔黏膜对膳食中脂肪的吸收,促使脂肪排除体外。
专利CN106853040A公开了一种治疗肥胖症的组合物,其中白花蛇人参20-40克、黄芪10-20克、白术5-10克、鹿茸50-80克、海马25-35克、冬虫夏草10-15克、蛤蚧20-30克、当归50-70克、何首乌20-25克、阿胶20-50克、北沙参30-45克、枸杞70-120克、女贞子10-20克。该发明是主要以黄芪、枸杞为主的减肥中药,而且没有具体说明其有益效果。
专利CN106070486A公开了一种减肥饼干,原料的重量比为:小麦粉100份,白砂糖18份,乳粉3份,食盐0.7份,脱水荷叶碎片9份,植物起酥油11份,小苏打1份,淀粉8份,鸡蛋9份,柚皮苷二氢查尔酮0.05份,蒿琥酯0.04份,黄芪甲甙0.07份,漆黄素0.7份,苦参碱0.07份,积雪草酸0.1份。该专利没有具体公开其有益效果。
目前上市的减肥药多以减少脂肪吸收或抑制食欲为主,对改善肥胖引起的代谢性疾病比如糖尿病、脂肪肝等效果不佳。而且现有减肥药长期服用,都会产生肝损伤;还常常导致免疫力下降。
发明内容
有鉴于此,本发明目的在于提供一种漆黄素磷脂复合物及其减肥药物/保健食品,所述漆黄素磷脂复合物是漆黄素与磷脂进行反应得到一种水溶性提高和生物利用度提高的漆黄素磷脂复合物。该漆黄素磷脂复合物使用了漆黄素具有瘦素增敏作用的特性,作为减肥产品,长期服用不会产生肝损伤和免疫力下降的副作用,而且该漆黄素磷脂复合物还克服了漆黄素水溶性和生物利用度较差的技术问题。
漆黄素是一种黄酮类化合物,难溶于水、四氯化碳和石油醚,易溶于丙酮、乙酸等溶剂,广泛存在于草莓、苹果、洋葱、黄瓜等水果和蔬菜中,但含量很低,具广泛的药理活性,如抗炎、抗氧化、抗凝血、抗血栓、解痉、治疗糖尿病肾损伤等。近年来研究发现,漆黄素可以通过抑制肿瘤细胞增殖和信号转导通路、诱导肿瘤细胞凋亡等途径发挥抗肿瘤作用,故其日益受到大家的关注。
所述漆黄素磷脂复合物的制备方法包括:将漆黄素和磷脂按重量比1:1-4溶于有机溶剂中,加热进行反应,所述漆黄素重量浓度为5-80mg/ml。
进一步,所述磷脂为卵磷脂、脑磷脂、肌醇磷脂或磷脂酸中的一种或多种
进一步,所述反应溶剂为可以同时溶解漆黄素与卵磷脂的溶剂,所述溶剂优选为四氢呋喃、乙醇、甲醇、三氯甲烷、二氯甲烷、乙酸乙酯中的一种或多种。
进一步,所述反应的反应时间为1-5h,反应温度为30-60℃。
进一步,所述制备方法还包括反应结束后,将反应液减压蒸馏得所述漆黄素磷脂复合物。
在某些具体实施例中,所述反应在回流磁力搅拌的反应条件下进行反应。
在某些具体实施例中,反应结束后将反应液减压蒸馏除去反应溶剂,加入适量三氯甲烷,抽滤,将滤液继续减压蒸馏除去三氯甲烷,40℃真空干燥3h,得到漆黄素磷脂复合物。
本发明目的在于还提供一种避免肝损伤的减肥药物/保健食品,该减肥药物/保健食品可以显著影响高脂饮食模型(HFD)的体重、血糖、葡萄糖耐量、胰岛素耐量和HFD模型血清中总胆固醇(TC)、油三酯(TG)、非甾体脂肪酸(NEFA)、瘦素(Leptin)水平,而且还不会出现肝损伤和免疫力下降的副作用。
所述减肥药物/保健食品包括:按照重量百分计,漆黄素和/或漆黄素复合物为10-50%、枸杞提取物10-50%、决明子提取物10-50%、白茅根提取物10-50%、黄芪提取物10-50%;所述漆黄素复合物包括前任一所述的漆黄素磷脂复合物或漆黄素纳米结晶或漆黄素-环糊精复合物中的一种或多种。需要说明的是,此处的漆黄素磷脂复合物为减压蒸馏后的漆黄素磷脂复合物。
具体地,在某些实施例中,所述减肥药物/保健食品的小鼠给药量为≥20mg/kg漆黄素。
进一步,所述漆黄素纳米结晶为漆黄素与聚维酮K30、共聚维酮S630、十二烷基硫酸钠、泊洛沙姆188、卵磷脂、吐温80、没食子酸丙酯(PG)中的一种或多种研磨而成;所述漆黄素-环糊精复合物为漆黄素与α-环糊精、β-环糊精、γ-环糊精、麦芽糖基-β-环糊精、羟丙基-β-环糊精中的一种或多种制备而成。
进一步,所述漆黄素纳米结晶的制备方法包括:将稳定剂溶于水后与漆黄素混合研磨;所述稳定剂为聚维酮K30、共聚维酮S630、十二烷基硫酸钠、泊洛沙姆188、卵磷脂、吐温80、没食子酸丙酯(PG)中的一种或多种;所述漆黄素与所述稳定剂的重量比为1:0.1-1。
进一步,所述漆黄素纳米结晶的粒径为100-950nm。
进一步,所述漆黄素纳米结晶的制备方法还包括:在研磨机里进行研磨20-360min得到粒径为100-950nm的漆黄素纳米混悬液,用喷雾干燥或冷冻干燥进行得到漆黄素纳米结晶。
进一步,漆黄素纳米混悬液在干燥前加入5%的甘露醇。
进一步,所述漆黄素-环糊精复合物的制备方法包括:所述漆黄素-环糊精复合物的制备方法包括:将漆黄素与环糊精加入水中振荡、离心得上清液;所述环糊精为α-环糊精、β-环糊精、γ-环糊精、麦芽糖基-β-环糊精、羟丙基-β-环糊精中的一种或多种;所述漆黄素与环糊精的重量比为1:1-10。
进一步,所述振荡具体为:在25-60℃的水浴中振荡3h-72h,离心得上清液。
进一步,所述漆黄素-环糊精复合物的制备方法还包括:将上清液进行喷雾干燥或冷冻干燥,得到固体为漆黄素/环糊精复合物。
进一步,在所述上清液干燥前加入5%的甘露醇。
进一步,将所述漆黄素复合物与辅料混合制成颗粒,然后与枸杞提取物、决明子提取物、白茅根提取物、黄芪提取物混合;所述辅料为微晶纤维素、可溶性淀粉、预胶化淀粉、糊精、乳糖、甘露醇中的一种或多种;所述漆黄素复合物与辅料重量比为1:0.2-2。
进一步,将漆黄素和/或漆黄素复合物与微晶纤维素进行混合制粒,然后用30目筛进行过筛和整粒,后温度35±5℃烘干至水分低于7%。
进一步,所述减肥药物/保健食品为胶囊或片剂或微丸或颗粒剂制剂。
本发明还提供一种提高漆黄素水溶性的方法,该方法可以将漆黄素的的水溶性提高10倍。该方法包括:将漆黄素制备成前任一所述的漆黄素磷脂复合物或将漆黄素制备成前任一所述的减肥药物/保健食品;提高漆黄素的水溶性的方法还包括:将漆黄素制备成前任一所述的漆黄素纳米结晶或者将漆黄素制备成前任一所述的漆黄素-环糊精复合物。
本发明还提供一种提高漆黄素生物利用度的方法,该方法可以将漆黄素的生物利用度提高230%。该方法包括:将漆黄素制备成前任一所述的漆黄素磷脂复合物或将漆黄素制备成前任一所述的减肥药物/保健食品。提高漆黄素生物利用度的方法还包括:将漆黄素制备成前任一所述的漆黄素纳米结晶或者将漆黄素制备成前任一所述的漆黄素-环糊精复合物。
本发明中,术语“mg/kg漆黄素”为:1kg的服用者服用1mg漆黄素,如果是服用本发明中的漆黄素复合物或者保健食品,则要进行相应的折算。
本发明中,所涉及的“重量”“时间”“重量比”“重量百分数”“粒径”等表明物理或化学性质的数值,不包括由于仪器误差和操作误差导致的数值差,即是说由于仪器误差和操作误差导致的数值差范围也在本发明技术方案之中.
本发明中术语“重量浓度”为固体在液体中的比例,包括溶于溶剂和不溶于溶剂的部分,单位为w/v。
本发明中使用的“甘露醇”均为赋形剂,不会对产品产生影响疗效的影响。
本发明中术语“提取物”为一般释意,即对相关中药进行提取、浓缩、干燥后得到的提取物。
本发明有益效果在于:
本发明提供的减肥药物/保健食品明显降低高脂饮食引起肥胖模型的体重,与高脂饮食组对比,体重减少20%左右;还能显著降低高脂饮食模型的血糖水平;明显提高高脂饮食模型的葡萄糖耐受水平和胰岛素耐受水平;还能显著降低高脂饮食模型血清中的总胆固醇(TC)、油三酯(TG)、非甾体脂肪酸(NEFA)的含量;还能显著降低高脂饮食模型血清中的瘦素浓度,还能显著增加瘦素的敏感性;还能明显降低高脂饮食模型肝细胞中的脂肪沉积,降低炎性浸润;而且减重的同时还能够减轻代谢应激引起的肝损伤,安全性高。
本发明提供的减肥药物/保健食品还可以改善应肥胖气虚造成的身体代谢功能不畅。
本发明提供的漆黄素磷脂复合物(漆黄素磷脂复合物)的将漆黄素的水溶性提高了10倍;将漆黄素的生物利用度提高了230%。
附图说明
图1为复方胶囊对高脂饮食小鼠体重的影响。
图2为复方胶囊对高脂饮食小鼠血糖的影响。
图3为复方胶囊对高脂饮食小鼠葡萄糖耐量的影响。
图4为复方胶囊对高脂饮食小鼠胰岛素耐量的影响。
图5为复方胶囊对HFD小鼠血清中TC水平的影响。
图6为复方胶囊对HFD小鼠血清中TG水平的影响。
图7为复方胶囊对HFD小鼠血清中NEFA水平的影响。
图8为复方胶囊对HFD小鼠血清中瘦素(Leptin)水平的影响。
图9为复方胶囊对HFD小鼠肝脏组织形态的影响。
图10为漆黄素平均血药浓度-时间曲线。
具体实施方式
所举实施例是为了更好地对本发明进行说明,但并不是本发明的内容仅局限于所举实施例。所以熟悉本领域的技术人员根据上述发明内容对实施方案进行非本质的改进和调整,仍属于本发明的保护范围。
实施例1:漆黄素纳米结晶的制备
将4%的泊洛沙姆188(P 188)和0.5%的共聚维酮S 630溶于50ml纯化水中,搅拌至完全溶解,加入1%的没食子酸丙酯(PG),搅拌至完全溶解,备用。取该混合溶液46g,漆黄素4g,加入研磨罐中,加入研磨球,研磨200min后,过筛分离出漆黄素纳米混悬液,加入5%的甘露醇,放入冷冻干燥机里先预冻24h,再进行干燥得到漆黄素纳米结晶。
测定漆黄素纳米结晶冻干品在磷酸盐缓冲液(pH=6.8)的溶解度。分别吸取磷酸盐缓冲液(pH=6.8),0.5%吐温80溶液,向其中加入过量的漆黄素和漆黄素纳米结晶冻干品,连续涡旋震荡48h后,离心后取上清液2m L,用0.22μm微孔滤膜过滤,释放介质稀释后测定其吸光度,计算出溶解度如表1,溶解度提高了7倍。
表1漆黄素和漆黄素纳米结晶在水中的溶解度
样品 | 表观溶解度mg/ml |
漆黄素 | 0.15 |
漆黄素纳米结晶 | 1.01 |
实施例2:漆黄素磷脂复合物的制备
将300mg漆黄素和1.2g大豆卵磷脂溶于30ml四氢呋喃,在40℃下,回流磁力搅拌反应2h。反应结束后将反应液减压蒸馏除去反应溶剂,加入适量三氯甲烷,抽滤,将滤液继续减压蒸馏除去三氯甲烷,40℃真空干燥3h,得到漆黄素磷脂复合物固体。复合物在正辛醇和水中的溶解度见表2,溶解度分别提高约9倍和8倍。
表2漆黄素及其磷脂复合物在正辛醇和水中的溶解度
实施例3漆黄素-环糊精复合物的制备
将0.286g漆黄素与1.38gβ-环糊精(β-CD)加入25ml纯水中,并在30℃的水浴中振荡72h,离心,得上清液,加入5%的甘露醇,放入冷冻干燥机里先预冻24h,再进行干燥得到漆黄素/环糊精复合物。复合物在水中的溶解度见表3,溶解度提高了9倍。
表3漆黄素和漆黄素/环糊精复合物在水中的溶解度
样品 | 表观溶解度mg/ml |
漆黄素 | 0.15 |
漆黄素/环糊精复合物 | 1.32 |
实施例4复方胶囊1的制备
将15份漆黄素与10份的微晶纤维素进行混合,制粒,用30目筛进行过筛和整粒,用真空干燥方法烘干颗粒,温度35℃,烘干至水分低于7%。将所制得25份漆黄素颗粒与30份枸杞提取物、10份决明子提取物、25份白茅根提取物、10份黄芪提取物进行混合,灌装胶囊。
实施例5复方胶囊2的制备
将30份漆黄素纳米结晶与10份的微晶纤维素进行混合,制粒,用30目筛进行过筛和整粒,用真空干燥方法烘干颗粒,温度35℃,烘干至水分低于7%。将所制得40份漆黄素颗粒与20份枸杞提取物、10份决明子提取物、15份白茅根提取物、15份黄芪提取物进行混合,灌装胶囊。
实施例6复方胶囊3的制备
将20份漆黄素磷脂复合物与20份的微晶纤维素进行混合,制粒,用30目筛进行过筛和整粒,用真空干燥方法烘干颗粒,温度35℃,烘干至水分低于7%。将所制得40份漆黄素颗粒与25份枸杞提取物、10份决明子提取物、10份白茅根提取物、15份黄芪提取物进行混合,灌装胶囊。
实施例7复方胶囊4的制备
将15份漆黄素磷脂复合物与15份的微晶纤维素进行混合,制粒,用30目筛进行过筛和整粒,用真空干燥方法烘干颗粒,温度35℃,烘干至水分低于7%。将所制得30份漆黄素颗粒与10份枸杞提取物、15份决明子提取物、20份白茅根提取物、25份黄芪提取物进行混合,灌装胶囊。
实施例8复方胶囊对高脂饮食诱导的肥胖小鼠的影响研究
(1)实验设计和实验方法
采用周龄为6-8周的雄性C57BL/6小鼠,体重控制在20-25g。在开始动物实验之前,让小鼠在受控环境(25℃±2℃、50%±5%湿度)下,无特定病原体(SPF)屏障设施中饲养,标准的12小时光-暗循环,在笼子中自由进食且有充足的标准食物和水。
以单体漆黄素的量为基准,然后按照实施例4-实施例7复方胶囊的份数进行复配得到的颗粒进行试验。把小鼠随机分成6组:(a)正常对照组(Con);(b)高脂饮食组(HFD);(c)高脂饮食+复方胶囊1(HFD+F1,20mg/kg漆黄素);(d)高脂饮食+复方胶囊2(HFD+F2,40mg/kg漆黄素);(e)高脂饮食+复方胶囊3(HFD+F3,40mg/kg漆黄素);(f)高脂饮食+复方胶囊4(HFD+F4,40mg/kg漆黄素)。
在准备实验时,将模型组老鼠饲料改为高脂饲料直到实验动物被解剖用于进一步的研究。为了研究漆黄素的药理作用,每天在9:00-10:00时间段根据分组分别进行不同药物灌胃实验组小鼠(0.5ml/100g体重),每天灌服一次,持续16周。每天记录食物摄入量。每隔4周测定小鼠体重、血糖和胰岛素水平。在最后一次灌胃后取小鼠眼球血,在温度为4℃,转速为10000rpm/min条件下离心10min,收集小鼠血清进行生物化学测定。测量小鼠心脏组织和腹股沟脂肪组织重量。
(2)复方胶囊对高脂饮食诱导的肥胖小鼠的体重影响
每天在9:00-10:00时间段根据分组分别进行不同药物灌胃实验组小鼠(0.5ml/100g体重),每天灌服一次,持续16周。每天记录食物摄入量。每隔4周测定小鼠体重,结果如图1。复方胶囊组的小鼠体重比单纯高脂饮食组的小鼠体重明显减少了,比正常组的小鼠体重略高一点。
(3)复方胶囊对高脂饮食诱导的肥胖小鼠胰岛素耐量和葡萄糖耐量的影响
每天在9:00-10:00时间段根据分组分别进行不同药物灌胃实验组小鼠(0.5ml/100g体重),每天灌服一次,持续16周。每天记录食物摄入量。每隔8周测定小鼠血糖和胰岛素水平,结果如图2。结果表明,复方胶囊能显著降低高脂饮食小鼠的血糖水平。
口服葡萄糖耐量试验(OGTT)是将小鼠禁食8h后,小鼠口服葡萄糖(2g/kg体重),且在指定时间取尾静脉血,接着用邻甲苯胺试剂测定血糖水平,结果如如图3。胰岛素耐量试验(ITT)是让小鼠禁食8h后,给小鼠腹腔注射胰岛素(1U/kg体重),最后在指定时间内计算血糖水平,结果如图4。复方胶囊能明显提高高脂饮食小鼠的葡萄糖耐受和胰岛素耐受。
(4)复方胶囊对高脂饮食诱导的肥胖小鼠血清总胆固醇、低密度脂蛋白胆固醇和甘油三酯的影响
在最后一次灌胃后取小鼠眼球血,在温度为4℃,转速为10000rpm/min条件下离心10min,收集小鼠血清,测定血清的中总胆固醇(TC)(如图5所示)、甘油三酯(TG)(如图6所示)和非甾体脂肪酸(NEFA)(如图7所示)的含量。复方胶囊2,3,4能显著降低高脂饮食小鼠血清中的总胆固醇(TC)、油三酯(TG)、非甾体脂肪酸(NEFA)的含量。
(5)复方胶囊对高脂饮食诱导的肥胖小鼠血清瘦素浓度的影响
在最后一次灌胃后取小鼠眼球血,在温度为4℃,转速为10000rpm/min条件下离心10min,收集小鼠血清,测定血清的中瘦素(Leptin)(如图8所示)的含量。结果表明,复方胶囊能显著降低高脂饮食小鼠血清中的瘦素浓度,能显著增加瘦素的敏感性。
(6)复方胶囊对高脂饮食诱导的肥胖小鼠肝脏组织形态的影响
在最后一次灌胃后解剖小鼠,取其新鲜肝脏组织,置于4%多聚甲醛组织固定液或中性福尔马林固定液中,浸泡24-48小时,然后取适量组织进行H&E染色分析(如图9所示)。复方胶囊能明显降低高脂饮食小鼠肝细胞中的脂肪沉积,降低炎性浸润。
实施例9漆黄素及其磷脂复合物的生物利用度实验
取SD大鼠12只,等分为2组,分别按照40mg·kg-1(以漆黄素计)灌胃给予漆黄素磷脂复合物和漆黄素原料药,分别于给药后20、40min和1、2、3、4、6、8h眼底静脉丛取血0.5-1.0mL,每次取血后给大鼠补充等量生理盐水,分离血浆,-80℃冷冻,备用。进行HPLC测定,求算药动学参数,结果见表4,平均血药浓度-时间曲线见图10。
由表4和图10可知,漆黄素磷脂复合物的Cmax和AUC明显高于漆黄素原料药,说明本处方和制备工艺能明显促进漆黄素的吸收,提高其生物利用度。
表4漆黄素大鼠灌胃给药药动学参数
参数名称 | 漆黄素磷脂复合物 | 原料组 |
AUC(0-t)/μg·L<sup>-1</sup> | 1486.21±229.118 | 618.336±121.156 |
AUC(0-∞)/μg·L<sup>-1</sup> | 1859.322±579.128 | 2196.784±1265.254 |
MRT(0-t)/h | 3.654±0.109 | 4.752±0.126 |
MRT(0-∞)/h | 5.784±2.933 | 23.47±18.655 |
t<sub>1/2z</sub>/h | 3.442±2.788 | 15.246±13.298 |
T<sub>max</sub>/h | 3 | 3±1.108 |
Cmax/μg·L<sup>-1</sup> | 519.775±48.397 | 91.321±16.857 |
最后说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的宗旨和范围,其均应涵盖在本发明的权利要求范围当中。
Claims (10)
1.漆黄素磷脂复合物,其特征在于,所述漆黄素磷脂复合物的制备方法包括:将漆黄素和磷脂按重量比1:1-4溶于有机溶剂中,加热进行反应,所述漆黄素重量浓度为5-80mg/ml。
2.根据权利要求1所述的漆黄素磷脂复合物,其特征在于,所述磷脂为卵磷脂、脑磷脂、肌醇磷脂或磷脂酸中的一种或多种。
3.根据权利要求1所述的漆黄素磷脂复合物,其特征在于,所述有机溶剂为四氢呋喃、乙醇、甲醇、三氯甲烷、二氯甲烷、乙酸乙酯中的一种或多种。
4.根据权利要求1所述的漆黄素磷脂复合物,其特征在于,所述反应的反应时间为1-5h,反应温度为30-60℃。
5.一种避免肝损伤的减肥药物/保健食品,其特征在于,所述减肥药物/保健食品包括:按照重量百分计,漆黄素和/或漆黄素复合物为10-50%、枸杞提取物10-50%、决明子提取物10-50%、白茅根提取物10-50%、黄芪提取物10-50%;所述漆黄素复合物包括权利要求1-4任一所述的漆黄素磷脂复合物和/或漆黄素纳米结晶和/或漆黄素-环糊精复合物;所述漆黄素纳米结晶的制备方法包括:将稳定剂溶于水后与漆黄素混合研磨;所述稳定剂为聚维酮K30、共聚维酮S630、十二烷基硫酸钠、泊洛沙姆188、卵磷脂、吐温80、没食子酸丙酯(PG)中的一种或多种;所述漆黄素与所述稳定剂的重量比为1:0.1-1。
6.根据权利要求5所述的减肥药/保健食品,其特征在于,所述漆黄素纳米结晶的粒径为100-950nm。
7.根据权利要求5-6任一所述的减肥药物/保健食品,其特征在于,将所述漆黄素复合物与药学上可接受的辅料混合制成颗粒,然后与枸杞提取物、决明子提取物、白茅根提取物、黄芪提取物混合;所述漆黄素复合物与所述药学上可接受的辅料重量比为1:0.2-2。
8.根据权利要求7所述的减肥药物/保健食品,其特征在于,所述减肥药物/保健食品为胶囊或片剂或微丸或颗粒剂制剂。
9.一种提高漆黄素水溶性的方法,其特征在于,将漆黄素制备成权利要求1-4任一所述的漆黄素磷脂复合物或将漆黄素制备成权利要求5-8任一所述的减肥药物/保健食品。
10.一种提高漆黄素生物利用度的方法,其特征在于,将漆黄素制备成权利要求1-4任一所述的漆黄素磷脂复合物或将漆黄素制备成权利要求5-8任一所述的减肥药物/保健食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110935836.0A CN113663083A (zh) | 2021-08-16 | 2021-08-16 | 一种漆黄素磷脂复合物和减肥药物/保健食品及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110935836.0A CN113663083A (zh) | 2021-08-16 | 2021-08-16 | 一种漆黄素磷脂复合物和减肥药物/保健食品及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113663083A true CN113663083A (zh) | 2021-11-19 |
Family
ID=78543052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110935836.0A Pending CN113663083A (zh) | 2021-08-16 | 2021-08-16 | 一种漆黄素磷脂复合物和减肥药物/保健食品及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113663083A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114432460A (zh) * | 2022-03-28 | 2022-05-06 | 中国药科大学 | 一种漆黄素包合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101095670A (zh) * | 2006-06-28 | 2008-01-02 | 黑龙江大学 | 木犀草素磷脂复合物及其制备方法和应用 |
CN101698028A (zh) * | 2009-11-03 | 2010-04-28 | 苏庆文 | 一种降脂减肥组合物及其制备方法 |
CN103055313A (zh) * | 2005-07-07 | 2013-04-24 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
CN103702675A (zh) * | 2010-08-11 | 2014-04-02 | Azi有限公司 | 具有增加含量的活性类黄酮化合物的漆树提取物及其制备方法 |
CN106070486A (zh) * | 2016-08-23 | 2016-11-09 | 开平市水口镇卡摩商行 | 一种减肥饼干 |
KR20180099263A (ko) * | 2017-02-28 | 2018-09-05 | 경남대학교 산학협력단 | 피세틴을 포함하는 피부건강용 조성물 |
-
2021
- 2021-08-16 CN CN202110935836.0A patent/CN113663083A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103055313A (zh) * | 2005-07-07 | 2013-04-24 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
CN101095670A (zh) * | 2006-06-28 | 2008-01-02 | 黑龙江大学 | 木犀草素磷脂复合物及其制备方法和应用 |
CN101698028A (zh) * | 2009-11-03 | 2010-04-28 | 苏庆文 | 一种降脂减肥组合物及其制备方法 |
CN103702675A (zh) * | 2010-08-11 | 2014-04-02 | Azi有限公司 | 具有增加含量的活性类黄酮化合物的漆树提取物及其制备方法 |
CN106070486A (zh) * | 2016-08-23 | 2016-11-09 | 开平市水口镇卡摩商行 | 一种减肥饼干 |
KR20180099263A (ko) * | 2017-02-28 | 2018-09-05 | 경남대학교 산학협력단 | 피세틴을 포함하는 피부건강용 조성물 |
Non-Patent Citations (3)
Title |
---|
CHANG HWA JUNG等: "Fisetin regulates obesity by targeting mTORC1 signaling", 《JOURNAL OF NUTRITIONAL BIOCHEMISTRY》 * |
MYUNG-SOO SHON等: "Potential of Fisetin as a Nutri-cosmetics Material through Evaluating Anti-oxidant and Anti-adipogenic Activities", 《AJBC》 * |
张克霞等: "黄酮类化合物磷脂复合物的研究进展", 《沈阳药科大学学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114432460A (zh) * | 2022-03-28 | 2022-05-06 | 中国药科大学 | 一种漆黄素包合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105983015B (zh) | 一种含有水飞蓟宾、ve的药物组合物 | |
CN102670864A (zh) | 治疗心脑血管疾病和糖尿病的抗氧化功能的药物组合物 | |
KR20160117425A (ko) | 광동금전초 총플라보노이드를 함유하는 내복 고체 제제 및 그의 용도 | |
CN113663083A (zh) | 一种漆黄素磷脂复合物和减肥药物/保健食品及其应用 | |
CN107049944B (zh) | 一种可实现索拉非尼和姜黄素同时给药的聚合物胶束及其制备方法 | |
CN111317750A (zh) | 番荔枝种子总内酯在制备防治糖尿病的药物中的应用 | |
CN112472723A (zh) | 一种包含海鞘内囊的产品及其制备方法 | |
CN110117332B (zh) | 一种分离的防风多糖及其用途 | |
CN108670986A (zh) | 一种具有降糖活性的蛹虫草提取物及其制备方法和应用 | |
CN103432124B (zh) | 氧化苦参碱在制备防治糖尿病肾病药物中的应用 | |
CN108186693B (zh) | 一种降尿酸或治疗高尿酸血症的蝙蝠蛾拟青霉活性物质的制备方法和该方法制备得到活性物质及其用途 | |
CN101411711B (zh) | 泽泻醇a和泽泻醇a 24-乙酸酯组成的组合物及应用 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN1907432A (zh) | 天麻多糖在保健品和药物中的应用 | |
CN102145076B (zh) | 地黄及其提取物的制药用途 | |
CN109364049A (zh) | 大黄素及大黄素与虎杖苷组合在治疗代谢综合征中的应用 | |
CN107126450B (zh) | 鼠麹草提取物、鼠麹草有效物质富集物,制备方法与应用 | |
CN111450143A (zh) | 小叶榕提取物在制备预防和/或治疗肝脏病变的药物中的用途 | |
CN109125421A (zh) | 虎杖及虎杖苷在治疗代谢综合征中的应用 | |
CN1220510C (zh) | 一种益气补血养心安神的中成药及其制备方法质量控制方法 | |
CN105687497B (zh) | 含莲子心黄酮类化合物的组合物及其在降血脂方面的应用 | |
CN116421634B (zh) | 一种Cs-4虫草菌粉提取物及其制备方法和应用 | |
CN110721193B (zh) | 锁阳总多糖在制备治疗哮喘药物中的应用 | |
CN108186910A (zh) | 一种具有降血糖功效的复方铁皮石斛片及其制备方法 | |
CN113796542B (zh) | 海参卵黄蛋白在制备缓解结肠炎的功能性食品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |